146 related articles for article (PubMed ID: 21131747)
1. PET/CT in pediatric oncology.
Samuel AM
Indian J Cancer; 2010; 47(4):360-70. PubMed ID: 21131747
[TBL] [Abstract][Full Text] [Related]
2. PET and PET/CT in pediatric oncology.
Jadvar H; Connolly LP; Fahey FH; Shulkin BL
Semin Nucl Med; 2007 Sep; 37(5):316-31. PubMed ID: 17707239
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
4. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
5. Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature.
Dong MJ; Zhao K; Lin XT; Zhao J; Ruan LX; Liu ZF
Nucl Med Commun; 2008 Sep; 29(9):791-802. PubMed ID: 18677207
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
[TBL] [Abstract][Full Text] [Related]
7. Assessing tumor response to therapy.
Weber WA
J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
[TBL] [Abstract][Full Text] [Related]
8. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
9. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
10. Clinical applications of PET and PET/CT in pediatric malignancies.
Kumar R; Shandal V; Shamim SA; Halanaik D; Malhotra A
Expert Rev Anticancer Ther; 2010 May; 10(5):755-68. PubMed ID: 20470007
[TBL] [Abstract][Full Text] [Related]
11. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
12. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
13. [Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and non-neoplastic lesions on MRI imaging].
Cai L; Gao S; Li DC; Li YS; Chen QS; Xing XL
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):134-8. PubMed ID: 19538892
[TBL] [Abstract][Full Text] [Related]
14. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
Schmidt GP; Kramer H; Reiser MF; Glaser C
Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
[TBL] [Abstract][Full Text] [Related]
15. The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers.
Avril N; Dambha F; Murray I; Shamash J; Powles T; Sahdev A
Int J Urol; 2010 Jun; 17(6):501-11. PubMed ID: 20370848
[TBL] [Abstract][Full Text] [Related]
16. Evolving role of 18F-FDG-PET/CT for the body tumor and metastases in pediatrics.
Chen Z; Li X; Li F; Ouyang Q; Yu T
Eur J Radiol; 2010 Sep; 75(3):329-35. PubMed ID: 20576385
[TBL] [Abstract][Full Text] [Related]
17. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries.
Schwarz JK; Grigsby PW; Dehdashti F; Delbeke D
J Nucl Med; 2009 May; 50 Suppl 1():64S-73S. PubMed ID: 19380409
[TBL] [Abstract][Full Text] [Related]
18. [Correlation of FDG-PET and MRI/CT with histopathology in primary diagnosis, lymph node staging and diagnosis of recurrency of head and neck cancer].
Pöpperl G; Lang S; Dagdelen O; Jäger L; Tiling R; Hahn K; Tatsch K
Rofo; 2002 Jun; 174(6):714-20. PubMed ID: 12063600
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET/CT in pediatric solid tumors.
Franzius C
Q J Nucl Med Mol Imaging; 2010 Aug; 54(4):401-10. PubMed ID: 20823808
[TBL] [Abstract][Full Text] [Related]
20. Nuclear Medicine in Pediatric and Adolescent Tumors.
Kiratli PÖ; Tuncel M; Bar-Sever Z
Semin Nucl Med; 2016 Jul; 46(4):308-23. PubMed ID: 27237441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]